A 56-year-old woman with long-standing type 2 diabetes and established coronary artery disease is seen in a family medicine clinic. Her HbA1c is 7.8% on maximally tolerated metformin. eGFR is 60 mL/min/1.73 m² and urinary albumin-creatinine ratio is 6 mg/mmol. According to Diabetes Canada, which additional pharmacologic agent is preferred to reduce cardiovascular risk?